PhaseBio Pharmaceuticals PHAS Stock
PhaseBio Pharmaceuticals Price Chart
PhaseBio Pharmaceuticals PHAS Financial and Trading Overview
| PhaseBio Pharmaceuticals stock price | 0.07 USD |
| Previous Close | 0.07 USD |
| Open | 0.08 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 1100 |
| Day's Range | 0.07 - 0.09 USD |
| 52 Week Range | 0.04 - 4.08 USD |
| Volume | 8.6M USD |
| Avg. Volume | 1.79M USD |
| Market Cap | 3.5M USD |
| Beta (5Y Monthly) | 2.869146 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1 USD |
PHAS Valuation Measures
| Enterprise Value | 2.72M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.06613208 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.2726808 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 3.329 |
| Enterprise Value/EBITDA | -0.027 |
Trading Information
PhaseBio Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 2.869146 |
| 52-Week Change | -97.019% |
| S&P500 52-Week Change | -17.95% |
| 52 Week High | 4.08 USD |
| 52 Week Low | 0.04 USD |
| 50-Day Moving Average | 0.43 USD |
| 200-Day Moving Average | 0.91 USD |
PHAS Share Statistics
| Avg. Volume (3 month) | 1.79M USD |
| Avg. Daily Volume (10-Days) | 5.62M USD |
| Shares Outstanding | 49.86M |
| Float | 34.41M |
| Short Ratio | 1.89 |
| % Held by Insiders | 6.72% |
| % Held by Institutions | 55.20% |
| Shares Short | 2.07M |
| Short % of Float | 5.11% |
| Short % of Shares Outstanding | 4.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2021 |
| Most Recent Quarter (mrq) | June 30, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -12738.63% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -106.065% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 818K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | -98.00000000000000000000000000000000% |
| Gross Profit (ttm) | -91276000 USD |
| EBITDA | -102262000 USD |
| Net Income Avi to Common (ttm) | -102840000 USD |
| Diluted EPS (ttm) | -2.38 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 7.8M USD |
| Total Cash Per Share (mrq) | 0.16 USD |
| Total Debt (mrq) | 5.37M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.469 |
| Book Value Per Share (mrq) | -2.355 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -59421000 USD |
| Levered Free Cash Flow (ttm) | -33679248 USD |
Profile of PhaseBio Pharmaceuticals
| Country | United States |
| State | PA |
| City | Malvern |
| Address | 1 Great Valley Parkway |
| ZIP | 19355 |
| Phone | 610 981 6500 |
| Website | https://phasebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 60 |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Q&A For PhaseBio Pharmaceuticals Stock
What is a current PHAS stock price?
PhaseBio Pharmaceuticals PHAS stock price today per share is 0.07 USD.
How to purchase PhaseBio Pharmaceuticals stock?
You can buy PHAS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PhaseBio Pharmaceuticals?
The stock symbol or ticker of PhaseBio Pharmaceuticals is PHAS.
Which industry does the PhaseBio Pharmaceuticals company belong to?
The PhaseBio Pharmaceuticals industry is Biotechnology.
How many shares does PhaseBio Pharmaceuticals have in circulation?
The max supply of PhaseBio Pharmaceuticals shares is 0.
What is PhaseBio Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
PhaseBio Pharmaceuticals PE Ratio is now.
What was PhaseBio Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
PhaseBio Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the PhaseBio Pharmaceuticals company belong to?
The PhaseBio Pharmaceuticals sector is Healthcare.
PhaseBio Pharmaceuticals PHAS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}